REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

Major Program
Supportive Care and Symptom Management
Sponsor
Dana-Farber Cancer Institute
Status
Not yet recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT06710548
The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors.

The name of the study groups in this research study are:

1. REVITALIZE
2. Educational Materials
Intervention
Educational Materials, REVITALIZE Intervention
Condition
Ovarian Cancer, Advanced Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Cancer, PARP Inhibitor, Fatigue Related to Cancer Treatment, Fatigue in Cancer Survivors
Investigators
Alexi A Wright, MD, MPH, David Andorsky, MD, Carolyn Lefkowits, MD, MPH, MS, Sarah Genung, BA, Joanna J Arch, PhD, Joanna Arch, PhD, Jill Mitchell, MSW PhD, Madeline Nealis, BA, Alexi Wright, MD, MPH

See list of participating sites